Skip to main navigation
Keros Therapeutics
About
About Us
Management
Board of Directors
Contact Us
Our Pipeline
Our Pipeline
Our Product Candidates
- KER-050
- KER-047
- KER-012
Our Science
TGF-β Biology & Role in Diseases
Hematology Franchise
- KER-047 for Treatment of Functional Iron Deficiency
- KER-050 for Treatment of Ineffective Hematopoiesis
Pulmonary & Cardiovascular Franchise
- KER-012 for Treatment of Pulmonary and Cardiovascular Disorders
Investors and Media
Overview
Press Releases
Events & Presentations
Stock Information
Analyst Coverage
SEC Filings
Annual Reports
Corporate Governance
Investor FAQ
Investor Contact
Email Alerts
Careers
Working at Keros
Current Opportunities
Benefits
Folder: About
Folder: Our Pipeline
Folder: Our Science
Folder: Investors and Media
Folder: Careers
Back
About Us
Management
Board of Directors
Contact Us
Back
Our Pipeline
Our Product Candidates
Back
- KER-050
- KER-047
- KER-012
Back
TGF-β Biology & Role in Diseases
Hematology Franchise
Pulmonary & Cardiovascular Franchise
Back
- KER-047 for Treatment of Functional Iron Deficiency
- KER-050 for Treatment of Ineffective Hematopoiesis
Back
- KER-012 for Treatment of Pulmonary and Cardiovascular Disorders
Back
Overview
Press Releases
Events & Presentations
Stock Information
Analyst Coverage
SEC Filings
Annual Reports
Corporate Governance
Investor FAQ
Investor Contact
Email Alerts
Back
Working at Keros
Current Opportunities
Benefits
banner image

Annual Reports

Annual Reports

Show all

2021

  • Annual Report 12.1 MB
  • Proxy Statement 566.4 KB
  • 10-K Form 3.3 MB

2020

  • Annual Report 3 MB
  • Proxy Statement 233.6 KB
  • 10-K Form 20.2 MB
Follicular_Lymphoma_in_Bone_Marrow image

Keros Therapeutics

1050 Waltham Street, Suite 302
Lexington, MA 02421
+1 (617) 314-6297

Terms of Use

Privacy Notice

Cookie Policy

Expanded Access Policy